Table 1.

Subject Characteristics

Group	No. of Subjects	% Male	Age at Tissue Collection, years Median [IQR]	Mean EF, %	Proportion on Medication
Group	No. of Subjects	% Male	Age at Tissue Collection, years Median [IQR]	Mean EF, %	PDE3i	Non-PDEi Inotrope^*	Digoxin	ACEi	Beta-blocker	Diuretic	Antiarrhythmic
Adult
Nonfailing (LV)	20	55	52 [15.5]	59	0.00	0.65	0.00	0.00	0.20	0.10	0.00
Dilated cardiomyopathy	38	74	47 [22.5]	13	0.39	0.59	0.83	0.56	0.36	0.97	0.32

Pediatric

Nonfailing (LV)	12	50	7.5 [7.9]	54	0.00	0.64	0.00	0.00	0.00	0.00	0.00
Dilated cardiomyopathy	33	36	3.1 [8.4]	23	0.73	0.27	0.42	0.85	0.13	0.94	0.21
Nonfailing (RV)	10	60	7.5 [9.7]	NA	0.00	0.56	0.00	0.00	0.22	0.00	0.00
Single right ventricle	18	67	5.6 [4.7]	NA	0.61	0.13	0.53	0.71	0.00	1.00	0.07

ACEi, angiotensin-converting enzyme inhibitor; EF, ejection fraction; IQR, interquartile range; LV, left ventricle; NA, not available; PDEi, phosphodiesterase inhibitor; RV, right ventricle.

Non-PDEi inotropes include dopamine, dobutamine, epinephrine, and norepinephrine.